AZN – astrazeneca plc ordinary shares (US:NASDAQ)

News

AstraZeneca Achieves Positive Phase III Results for COPD Drug [TheStreet.com]
Tozorakimab met primary endpoint in Phase III MIRANDA trial in patients with COPD
Astrazeneca (AZN) had its "overweight" rating reaffirmed by Morgan Stanley.
Guggenheim Lifts PT on AstraZeneca PLC (AZN) to 16,500 GBp From 16,000 GBp [Yahoo! Finance]
IMFINZI® (durvalumab) + IMJUDO® (tremelimumab-actl) improves PFS in early liver cancer
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com